Literature DB >> 22331460

Dmp1 physically interacts with p53 and positively regulates p53's stability, nuclear localization, and function.

Donna P Frazier1, Robert D Kendig, Fumitake Kai, Dejan Maglic, Takayuki Sugiyama, Rachel L Morgan, Elizabeth A Fry, Sarah J Lagedrost, Guangchao Sui, Kazushi Inoue.   

Abstract

The transcription factor Dmp1 is a Ras/HER2-activated haplo-insufficient tumor suppressor that activates the Arf/p53 pathway of cell-cycle arrest. Recent evidence suggests that Dmp1 may activate p53 independently of Arf in certain cell types. Here, we report findings supporting this concept with the definition of an Arf-independent function for Dmp1 in tumor suppression. We found that Dmp1 and p53 can interact directly in mammalian cells via the carboxyl-terminus of p53 and the DNA-binding domain of Dmp1. Expression of Dmp1 antagonized ubiquitination of p53 by Mdm2 and promoted nuclear localization of p53. Dmp1-p53 binding significantly increased the level of p53, independent of the DNA-binding activity of Dmp1. Mechanistically, p53 target genes were activated synergistically by the coexpression of Dmp1 and p53 in p53(-/-);Arf(-/-) cells, and genotoxic responses of these genes were hampered more dramatically in Dmp1(-/-) and p53(-/-) cells than in Arf(-/-) cells. Together, our findings identify a robust new mechanism of p53 activation mediated by direct physical interaction between Dmp1 and p53. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22331460      PMCID: PMC3319807          DOI: 10.1158/0008-5472.CAN-11-2410

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

Review 1.  The ARF/p53 pathway.

Authors:  C J Sherr; J D Weber
Journal:  Curr Opin Genet Dev       Date:  2000-02       Impact factor: 5.578

2.  Mono- versus polyubiquitination: differential control of p53 fate by Mdm2.

Authors:  Muyang Li; Christopher L Brooks; Foon Wu-Baer; Delin Chen; Richard Baer; Wei Gu
Journal:  Science       Date:  2003-12-12       Impact factor: 47.728

Review 3.  The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor.

Authors:  James J Manfredi
Journal:  Genes Dev       Date:  2010-08-01       Impact factor: 11.361

4.  Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas.

Authors:  K Inoue; F Zindy; D H Randle; J E Rehg; C J Sherr
Journal:  Genes Dev       Date:  2001-11-15       Impact factor: 11.361

5.  Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis.

Authors:  K Inoue; R Wen; J E Rehg; M Adachi; J L Cleveland; M F Roussel; C J Sherr
Journal:  Genes Dev       Date:  2000-07-15       Impact factor: 11.361

Review 6.  p53 and ARF: unexpected players in autophagy.

Authors:  Gregor M Balaburski; Robert D Hontz; Maureen E Murphy
Journal:  Trends Cell Biol       Date:  2010-03-19       Impact factor: 20.808

7.  Critical roles of DMP1 in human epidermal growth factor receptor 2/neu-Arf-p53 signaling and breast cancer development.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Takayuki Sugiyama; Robert D Kendig; Donna P Frazier; Mark C Willingham; Kazushi Inoue
Journal:  Cancer Res       Date:  2010-11-09       Impact factor: 12.701

8.  TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer.

Authors:  Shinako Araki; Jacob A Eitel; Christopher N Batuello; Khadijeh Bijangi-Vishehsaraei; Xian-Jin Xie; David Danielpour; Karen E Pollok; David A Boothman; Lindsey D Mayo
Journal:  J Clin Invest       Date:  2009-12-01       Impact factor: 14.808

9.  The Arf-inducing transcription factor Dmp1 encodes a transcriptional activator of amphiregulin, thrombospondin-1, JunB and Egr1.

Authors:  Ali Mallakin; Takayuki Sugiyama; Fumitake Kai; Pankaj Taneja; Robert D Kendig; Donna P Frazier; Dejan Maglic; Lauren A Matise; Mark C Willingham; Kazushi Inoue
Journal:  Int J Cancer       Date:  2010-03-15       Impact factor: 7.396

10.  Yin Yang 1 is a negative regulator of p53.

Authors:  Guangchao Sui; El Bachir Affar; Yujiang Shi; Chrystelle Brignone; Nathan R Wall; Peng Yin; Mary Donohoe; Margaret P Luke; Dominica Calvo; Steven R Grossman; Yang Shi
Journal:  Cell       Date:  2004-06-25       Impact factor: 41.582

View more
  25 in total

1.  Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Cancer Invest       Date:  2018-11-05       Impact factor: 2.176

2.  Stabilization of the p53-DNA Complex by the Nuclear Protein Dmp1α.

Authors:  Robert D Kendig; Fumitake Kai; Elizabeth A Fry; Kazushi Inoue
Journal:  Cancer Invest       Date:  2017-04-13       Impact factor: 2.176

3.  Aberrant Expression of p14ARF in Human Cancers: A New Biomarker?

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Tumor Microenviron       Date:  2019-02-04

4.  Aberrant expression of cyclin D1 in cancer.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Sign Transduct Insights       Date:  2015-09-20

5.  Human DMTF1β antagonizes DMTF1α regulation of the p14(ARF) tumor suppressor and promotes cellular proliferation.

Authors:  Mario P Tschan; Elena A Federzoni; Aladin Haimovici; Christian Britschgi; Bettina A Moser; Jing Jin; Venkateshwar A Reddy; Dennis A Sheeter; Kimberlee M Fischer; Peiqing Sun; Bruce E Torbett
Journal:  Biochim Biophys Acta       Date:  2015-07-15

Review 6.  Transcription factors that interact with p53 and Mdm2.

Authors:  Kazushi Inoue; Elizabeth A Fry; Donna P Frazier
Journal:  Int J Cancer       Date:  2015-07-14       Impact factor: 7.396

Review 7.  Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu.

Authors:  Elizabeth A Fry; Pankaj Taneja; Kazushi Inoue
Journal:  Int J Cancer       Date:  2016-09-12       Impact factor: 7.396

8.  Aberrant expression of ETS1 and ETS2 proteins in cancer.

Authors:  Elizabeth A Fry; Kazushi Inoue
Journal:  Cancer Rep Rev       Date:  2018-04-23

9.  Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer.

Authors:  D Maglic; S Zhu; E A Fry; P Taneja; F Kai; R D Kendig; T Sugiyama; L D Miller; M C Willingham; K Inoue
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

10.  DMP1β, a splice isoform of the tumour suppressor DMP1 locus, induces proliferation and progression of breast cancer.

Authors:  Dejan Maglic; Daniel B Stovall; J Mark Cline; Elizabeth A Fry; Ali Mallakin; Pankaj Taneja; David L Caudell; Mark C Willingham; Guangchao Sui; Kazushi Inoue
Journal:  J Pathol       Date:  2015-02-09       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.